Lymphopenia in COVID-19: Therapeutic opportunities

Cell Biol Int. 2020 Sep;44(9):1792-1797. doi: 10.1002/cbin.11403. Epub 2020 Jun 3.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is uncontrollably spread all over the world. The host immune responses strongly try to confront it with all the potential cells and cytokines. With chronically condition of SARS-CoV-2, natural killer cells and T cells become exhausted and decreasing their count leads to lymphopenia. Inability to eradicate the infected organ makes hyperinitiation of the immune system, which releases the excessive inflammatory cytokines to compensate the exhausted one as well as the low lymphocytes counts; it consequently leads to the cytokine storm syndrome. These mechanisms and the potential therapeutic targeting are discussed in this paper.

Keywords: COVID-19; apoptosis; coronavirus; cytokine storm syndrome; inflammation; lymphopenia.

Publication types

  • Review

MeSH terms

  • Betacoronavirus / immunology*
  • COVID-19
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / therapy*
  • Cytokines / antagonists & inhibitors
  • Cytokines / immunology
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunotherapy / methods
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / immunology
  • Lymphopenia / epidemiology
  • Lymphopenia / immunology*
  • Lymphopenia / therapy*
  • Pandemics
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / immunology*
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Cytokines
  • Immunosuppressive Agents